What We Do

SJA works diligently to evaluate viable exit strategies aligned with capital market conditions while assessing company-specific factors—such as therapeutic indication, phase of development, regulatory pathway, and investor base. We match clients with appropriate financing vehicles, including M&A, IPOs, SPACs, and reverse mergers.

We maintain strong relationships with sell-side banks to identify public shells, submit winning proposals, and negotiate term sheets for private companies seeking listings via SPAC or reverse merger transactions.

Specialize in Private-To-Public Structured Transactions

  • Liquidity Focus – target exit / publicly traded vehicle within 12-36 months from initial investment
  • Initial Public Offerings (IPOs)
  • Alternative Public Offerings (APOs): SPACs / Reverse merger with a publicly traded company / Form-10
  • Public Financing Vehicles – Shelf Offerings (PIPE, S3, S1), ATM, equity lines

Achievements 2016-2022

  • Identified, awarded, negotiated, and closed a public shell / term sheet with Flex Pharma (FLRX) resulting in Salarius Listing on NASDAQ via a reverse merger
  • Facilitated a $10.9M equity line with Aspire Capital
  • Closed a $11M S1 offering with Ladenburg Thalmann Funding Salarius Pharmaceuticals through phase 1 / 2 clinical milestones
  • AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V Read full article here: https://hubs.ly/Q01qq2XC0